Role of oral midazolam as a procedural sedative in children aged 6 months to 12 years

Abhishek K. Phadke, Prameela Joji, Sandeep Kumar

Research output: Contribution to journalArticle

Abstract

Pediatric procedural sedation is a safe, effective and humane way to facilitate appropriate medical care. We conducted a prospective, open-label randomized controlled trial in 272 children in the age group of 6 months to 12 years who need to undergo a procedure requiring pain or anxiety management. The objective was to evaluate the efficacy and safety profile of oral midazolam in comparison with intravenous midazolam. Out of 272 children, 42.5% children underwent invasive procedures and the rest non-invasive. For non-invasive procedures, 79% subjects in the oral group were adequately sedated, compared to 63% in the intravenous group. For invasive procedures, 71% subjects were adequately sedated with oral midazolam and 78% in intravenous group. 85% procedures were successfully completed in oral group compared to 79% in intravenous. Occurrence of adverse effects like desaturation, apnea and paradoxical hyper agitation was less with oral midazolam compared to intravenous.

Original languageEnglish
Pages (from-to)P488-P495
JournalInternational Journal of Pharma and Bio Sciences
Volume5
Issue number4
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Midazolam
Hypnotics and Sedatives
Pediatrics
Health care
Labels
Apnea
Anxiety
Randomized Controlled Trials
Age Groups
Safety
Pain

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Cell Biology

Cite this

Phadke, Abhishek K. ; Joji, Prameela ; Kumar, Sandeep. / Role of oral midazolam as a procedural sedative in children aged 6 months to 12 years. In: International Journal of Pharma and Bio Sciences. 2014 ; Vol. 5, No. 4. pp. P488-P495.
@article{f5c56559e15f46babab9fbdf1761859e,
title = "Role of oral midazolam as a procedural sedative in children aged 6 months to 12 years",
abstract = "Pediatric procedural sedation is a safe, effective and humane way to facilitate appropriate medical care. We conducted a prospective, open-label randomized controlled trial in 272 children in the age group of 6 months to 12 years who need to undergo a procedure requiring pain or anxiety management. The objective was to evaluate the efficacy and safety profile of oral midazolam in comparison with intravenous midazolam. Out of 272 children, 42.5{\%} children underwent invasive procedures and the rest non-invasive. For non-invasive procedures, 79{\%} subjects in the oral group were adequately sedated, compared to 63{\%} in the intravenous group. For invasive procedures, 71{\%} subjects were adequately sedated with oral midazolam and 78{\%} in intravenous group. 85{\%} procedures were successfully completed in oral group compared to 79{\%} in intravenous. Occurrence of adverse effects like desaturation, apnea and paradoxical hyper agitation was less with oral midazolam compared to intravenous.",
author = "Phadke, {Abhishek K.} and Prameela Joji and Sandeep Kumar",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "P488--P495",
journal = "International Journal of Pharma and Bio Sciences",
issn = "0975-6299",
publisher = "International Journal of Pharma and Bio Sciences",
number = "4",

}

Role of oral midazolam as a procedural sedative in children aged 6 months to 12 years. / Phadke, Abhishek K.; Joji, Prameela; Kumar, Sandeep.

In: International Journal of Pharma and Bio Sciences, Vol. 5, No. 4, 01.01.2014, p. P488-P495.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of oral midazolam as a procedural sedative in children aged 6 months to 12 years

AU - Phadke, Abhishek K.

AU - Joji, Prameela

AU - Kumar, Sandeep

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pediatric procedural sedation is a safe, effective and humane way to facilitate appropriate medical care. We conducted a prospective, open-label randomized controlled trial in 272 children in the age group of 6 months to 12 years who need to undergo a procedure requiring pain or anxiety management. The objective was to evaluate the efficacy and safety profile of oral midazolam in comparison with intravenous midazolam. Out of 272 children, 42.5% children underwent invasive procedures and the rest non-invasive. For non-invasive procedures, 79% subjects in the oral group were adequately sedated, compared to 63% in the intravenous group. For invasive procedures, 71% subjects were adequately sedated with oral midazolam and 78% in intravenous group. 85% procedures were successfully completed in oral group compared to 79% in intravenous. Occurrence of adverse effects like desaturation, apnea and paradoxical hyper agitation was less with oral midazolam compared to intravenous.

AB - Pediatric procedural sedation is a safe, effective and humane way to facilitate appropriate medical care. We conducted a prospective, open-label randomized controlled trial in 272 children in the age group of 6 months to 12 years who need to undergo a procedure requiring pain or anxiety management. The objective was to evaluate the efficacy and safety profile of oral midazolam in comparison with intravenous midazolam. Out of 272 children, 42.5% children underwent invasive procedures and the rest non-invasive. For non-invasive procedures, 79% subjects in the oral group were adequately sedated, compared to 63% in the intravenous group. For invasive procedures, 71% subjects were adequately sedated with oral midazolam and 78% in intravenous group. 85% procedures were successfully completed in oral group compared to 79% in intravenous. Occurrence of adverse effects like desaturation, apnea and paradoxical hyper agitation was less with oral midazolam compared to intravenous.

UR - http://www.scopus.com/inward/record.url?scp=84907983715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907983715&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - P488-P495

JO - International Journal of Pharma and Bio Sciences

JF - International Journal of Pharma and Bio Sciences

SN - 0975-6299

IS - 4

ER -